#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14160	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2446	710.2	0	.	n	.	0	C451T	SNP	451	451	C	835	835	T	869	T,C	437,432	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14160	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2446	710.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1834	1834	T	930	T,G,C	926,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14160	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2446	710.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1568	1568	C	905	C,T,G,A	902,1,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24564	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	717.6	0	.	n	.	0	C964T	SNP	964	964	C	1650	1650	T	922	T,C	690,231	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24564	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	717.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	2023	2023	A	999	A,T,C	995,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24564	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	717.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2657	2657	C	848	C,T,A	846,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24564	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	717.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2731	2731	A	864	A,G,C	862,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24564	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	717.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3283	3283	C	857	C,G,A	855,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24564	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4267	717.6	0	HET	.	.	.	T695C	.	695	695	T	1381	1381	T	898	T,C	635,263	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	2218	folP	855	855	100.0	folP.l15.c4.ctg.1	2125	130.2	1	SNP	p	R229S	0	.	.	685	687	CGC	1287	1289	CGC	191;194;198	C;G,A;C	191;193,1;198	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4696	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3983	147.0	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1369	1371	ATA	162;160;160	A,G;T;A	161,1;160;160	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4696	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3983	147.0	1	SNP	p	S91F	0	.	.	271	273	TCC	892	894	TCC	166;166;164	T;C;C	166;166;164	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4696	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3983	147.0	1	SNP	p	D95G	0	.	.	283	285	GAC	904	906	GAC	167;168;167	G;A;C	167;168;167	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4696	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3983	147.0	1	SNP	p	D95N	0	.	.	283	285	GAC	904	906	GAC	167;168;167	G;A;C	167;168;167	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1942	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1752	138.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	861	863	CAC	243;242;243	C;A;C	243;242;243	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1942	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1752	138.0	1	SNP	p	G45D	0	.	.	133	135	GGC	681	683	GGC	235;233;234	G;G;C	234;232;234	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1038	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1466	88.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4740	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3387	174.1	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1650	1652	ATC	261;260;259	A;T;C	261;260;259	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4740	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3387	174.1	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1803	1805	GCA	246;245;246	G;C,T;A	246;244,1;246	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4740	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3387	174.1	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2286	2288	ATT	227;227;226	A,T;T;T	226,1;227;226	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4740	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3387	174.1	1	SNP	p	D86N	0	.	.	256	258	GAC	756	758	GAC	202;200;200	G;A;C,G	202;200;199,1	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4740	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3387	174.1	1	SNP	p	S87W	0	.	.	259	261	AGT	759	761	AGT	202;198;199	A;G;T	202;197;199	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4740	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3387	174.1	1	SNP	p	S87I	0	.	.	259	261	AGT	759	761	AGT	202;198;199	A;G;T	202;197;199	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4740	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3387	174.1	1	SNP	p	S87R	0	.	.	259	261	AGT	759	761	AGT	202;198;199	A;G;T	202;197;199	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4740	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3387	174.1	1	SNP	p	S88P	0	.	.	262	264	TCC	762	764	TCC	199;198;198	T;C;C	199;197;197	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4506	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3379	166.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1996	1998	GGC	215;214;212	G;G;C	215;214;212	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1407	1409	GCA	242;245;246	G;C,T,A;A	242;243,1,1;246	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1410	1412	ATC	242;242;243	A;T;C	242;242;243	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1422	1424	GTG	248;251;254	G;T;G	248;251;254	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1422	1424	GTG	248;251;254	G;T;G	248;251;254	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1926	1928	ACC	235;232;239	A,G,T;C;C,T,G	232,2,1;232;237,1,1	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1980	1982	GCG	242;241;237	G;C;G	242;241;237	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1980	1982	GCG	242;241;237	G;C;G	242;241;237	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2103	2105	GGT	227;226;229	G,A;G;T,C	226,1;226;228,1	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2112	2114	GGC	235;235;239	G;G;C	235;235;239	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4274	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2777	191.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2130	2132	CCG	237;238;239	C,A;C;G	236,1;238;239	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	5622	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3518	198.9	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1733	1735	ACG	222;219;219	A;C;G	222;218;218	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	5622	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3518	198.9	0	.	p	.	0	Y537C	NONSYN	1609	1611	TAC	2219	2221	TGC	248;250;251	T,C;G,T,A;C,T,A	247,1;248,1,1;249,1,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2312	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2302	125.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	820	820	C	165	C	165	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	539	2330	porB1a	984	984	94.13	porB1a.l15.c17.ctg.1	1720	168.0	0	.	p	.	0	M18T	NONSYN	52	54	ATG	529	531	ACG	118;116;113	A;C;G,A,C	118;116;110,2,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	539	2330	porB1a	984	984	94.13	porB1a.l15.c17.ctg.1	1720	168.0	0	.	p	.	0	T26A	NONSYN	76	78	ACC	553	555	GCC	113;113;110	G,A;C;C,A	112,1;113;109,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	539	2330	porB1a	984	984	94.13	porB1a.l15.c17.ctg.1	1720	168.0	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	571	573	CAA	105;105;106	C;A,G;A,G,C	105;104,1;104,1,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	539	2330	porB1a	984	984	94.13	porB1a.l15.c17.ctg.1	1720	168.0	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	577	579	TAC	100;99;95	T,G,C;A,G;C	98,1,1;98,1;95	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	539	2330	porB1a	984	984	94.13	porB1a.l15.c17.ctg.1	1720	168.0	0	.	p	.	0	A38del	DEL	112	112	G	589	589	G	95	G	95	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	539	2330	porB1a	984	984	94.13	porB1a.l15.c17.ctg.1	1720	168.0	0	.	p	.	0	Y39trunc	TRUNC	115	115	T	589	589	G	95	G	95	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	539	2330	porB1a	984	984	94.13	porB1a.l15.c17.ctg.1	1720	168.0	0	.	p	.	0	H40fs	FSHIFT	118	118	C	592	592	C	95	C	95	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	0	.	p	.	0	E48K	NONSYN	142	144	GAA	829	831	AAA	202;205;203	A;A;A,C	202;205;202,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	0	.	p	.	0	V75I	NONSYN	223	225	GTT	910	912	ATT	173;172;170	A,G;T;T	171,2;172;170	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	0	.	p	.	0	T89S	NONSYN	265	267	ACC	952	954	AGC	130;129;126	A;G,C;C	130;128,1;126	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	0	.	p	.	0	V98I	NONSYN	292	294	GTC	979	981	ATC	80;78;78	A,G;T;C	79,1;78;78	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	0	.	p	.	0	T106K	NONSYN	316	318	ACC	1003	1005	AAA	58;57;57	A;A;A	58;57;57	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	0	.	p	.	0	I107V	NONSYN	319	321	ATC	1006	1008	GTG	56;56;54	G;T;G	56;56;54	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	0	.	p	.	0	S111H	NONSYN	331	333	AGC	1018	1020	CAT	56;58;60	C;A;T	56;58;60	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	0	.	p	.	0	P115V	NONSYN	343	345	CCC	1030	1032	GTC	65;66;66	G;T;C	65;66;66	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	0	.	p	.	0	N118D	NONSYN	352	354	AAC	1039	1041	GAC	72;74;74	G;A;C	72;74;74	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	528	1256	porB1b	1035	359	94.15	porB1b.l15.c4.ctg.1	1896	82.6	1	SNP	p	G120K	0	.	.	358	360	GG	1045	1046	GG	77;76	G;G,C	77;75,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10158	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5410	233.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2223	2225	CAT	253;255;253	C;A;T,G	253;255;252,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1468	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1460	124.8	1	SNP	p	V57M	0	.	.	169	171	GTG	801	803	GTG	249;247;248	G;T;G,A	249;247;246,2	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
